C

    Codexis Inc (CDXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.70
    +0.11 (+6.92%)

    Market Cap: $174.11M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +21.10%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.10 - $-0.07
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.10-17.6%
    60d ago$-0.08+5.9%
    30d ago$-0.10-17.6%
    7d ago$-0.09+0.0%
    Current$-0.09
    Revenue Consensus
    $20M
    Range$17M - $22M
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    Revenue Consensus
    $26M
    Range$25M - $28M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.13$-0.17+23.53%Beat+18.8%
    Mar 26
    		$-0.10$-0.10+0.00%Beat+60.0%
    Dec 25
    		$0.14$-0.04+485.44%Beat+210.0%
    Sep 25
    		$-0.22$-0.13-69.23%Miss+24.1%
    Jun 25
    		$-0.16$-0.15-6.67%Miss+50.0%
    Mar 25
    		$-0.25$-0.21-19.05%Miss-56.3%
    Dec 24
    		$-0.13$-0.04-225.00%Miss-30.0%
    Sep 24
    		$-0.29$-0.21-38.10%Miss+6.5%
    Jun 24
    		$-0.32$-0.24-33.33%Miss-88.2%
    Mar 24
    		$-0.16$-0.14-14.29%Miss+52.9%
    Dec 23
    		$-0.10$-0.12+16.67%Beat+28.6%
    Sep 23
    		$-0.31$-0.26-19.23%Miss-106.7%
    Jun 23
    		$-0.17$-0.14-21.43%Miss-325.0%
    Mar 23
    		$-0.34$-0.25-36.00%Miss-161.5%
    Dec 22
    		$-0.14$-0.23+39.13%Beat+12.5%
    Sep 22
    		$-0.15$-0.16+6.25%Beat-600.0%
    Jun 22
    		$-0.04N/A+66.67%Beat-300.0%
    Mar 22
    		$-0.13$-0.15+13.33%Beat-44.4%
    Dec 21
    		$-0.16$-0.22+27.27%Beat-166.7%
    Sep 21
    		$0.03$-0.05+160.00%Beat+150.0%
    Jun 21
    		$-0.01N/A+91.67%Beat+85.7%
    Mar 21
    		$-0.09$-0.18+50.00%Beat+30.8%
    Dec 20
    		$-0.06$-0.12+50.00%Beat-400.0%
    Sep 20
    		$-0.06$-0.05-20.00%Miss-250.0%
    Jun 20
    		$-0.07$-0.13+46.15%Beat+12.5%
    Mar 20
    		$-0.13$-0.15+13.33%Beat-160.0%
    Dec 19
    		$0.02N/A-60.00%Miss+300.0%
    Sep 19
    		$0.04$-0.05+180.00%Beat+200.0%
    Jun 19
    		$-0.08$-0.07-14.29%Miss-300.0%
    Mar 19
    		$-0.05$-0.08+37.50%Beat+0.0%
    Dec 18
    		$-0.01N/A+66.67%Beat-150.0%
    Sep 18
    		$-0.04$-0.03-33.33%Miss+81.0%
    Jun 18
    		$-0.02N/A+75.00%Beat+84.6%
    Mar 18
    		$-0.05$-0.08+37.50%Beat+72.2%
    Dec 17
    		$0.02N/A-60.00%Miss+115.4%
    Sep 17
    		$-0.21$-0.15-40.00%Miss-800.0%
    Jun 17
    		$-0.13$-0.12-8.33%Miss-
    Mar 17
    		$-0.18$-0.14-28.57%Miss-
    Dec 16
    		$-0.13$-0.11-18.18%Miss-
    Sep 16
    		$0.03N/A+123.08%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.54EV/EBITDA-10.67x
    Price/FCF-12.71xFCF Yield-7.87%
    Profitability
    Profit Margin-39.60%Operating Margin-75.30%
    ROE-69.40%ROIC-42.09%
    Financial Health
    Debt/Equity1.34xInterest Coverage-8.91x
    Current Ratio3.06xQuick Ratio2.99x
    Trading Statistics
    Beta2.50Avg Volume1.11M
    52-Week High$2.9852-Week Low$0.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.63
    SMA 20$1.57
    SMA 50$1.90
    SMA 200$1.89
    EMA 10$1.63
    EMA 20$1.65
    EMA 50$1.83
    EMA 200$2.07

    MACD

    Line: -0.05Signal: -0.09Hist: 0.04

    ADX

    ADX: 23.5+DI: 16.9-DI: 19.0

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down16.0
    PSAR$1.52

    Bollinger Bands

    Upper Band$1.74
    Lower Band$1.40
    %B Position2146%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    50.9

    Momentum Oscillators

    Stoch %K61.8
    Stoch %D62.1
    Williams %R-22.8
    ROC (10d)6.9%
    Momentum0.11
    CCI (20d)84.6
    MFI (14d)75.9

    Volatility Measures

    ATR (14d)$0.11(6.6%)
    StdDev (20d)0.08
    Hist Vol58.4%(High)

    Volume Flow

    VWAP$1.66
    OBV30.5M
    AD Line-60.7M
    CMF (20d)-0.033

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.2x
    VWMA (20d)$1.58

    Pivot Points

    R3$1.75
    R2$1.72
    R1$1.65
    Pivot Point$1.62
    S1$1.55
    S2$1.52
    S3$1.45

    Advanced Oscillators

    TSI-12.42
    Ultimate Osc51.1
    KST-92.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.91M$15.25M$38.91M$8.60M$15.33M$7.54M$21.46M$12.83M$7.98M$17.07M$26.56M$9.28M
    Cost of Revenue$3.51M$2.06M$3.36M$2.46M$2.10M$2.73M$3.65M$4.32M$3.46M$4.86M$2.86M$2.25M
    Gross Profit$11.40M$13.18M$35.55M$6.14M$13.23M$4.81M$17.81M$8.52M$4.52M$12.22M$23.70M$7.03M
    Operating Expenses$22.63M$21.23M$21.59M$25.09M$26.09M$25.30M$25.15M$25.07M$27.25M$24.11M$23.42M$39.09M
    R&D$11.71M$11.45M$10.92M$13.87M$13.78M$12.94M$12.10M$11.51M$11.41M$11.25M$11.23M$13.66M
    SG&A$10.93M$9.78M$11.19M$11.22M$12.32M$12.36M$13.05M$13.57M$15.67M$12.86M$12.18M$12.30M
    Operating Income$-11,229,000$-8,043,000$13.96M$-18,949,000$-12,862,000$-20,486,000$-7,342,000$-16,557,000$-22,732,000$-11,888,000$282,000$-32,060,000
    Interest Income$535,000$665,000$656,000$634,000$584,000$751,000$940,000$849,000$972,000$909,000$906,000$1.06M
    Interest Expense$766,000$625,000$1.59M$658,000$400,000$191,000$3.03M$4.07M$13,000$0$7.44M$2.84M
    Income Before Tax$-11,995,000$-8,668,000$9.62M$-19,607,000$-13,262,000$-20,677,000$-10,372,000$-20,630,000$-22,745,000$-11,495,000$-7,157,000$-34,899,000
    Income Tax Expense$10,000$36,000$18,000$8,000$10,000$11,000$4,000$10,000$10,000$10,000$35,000$9,000
    Net Income$-12,005,000$-8,704,000$9.60M$-19,615,000$-13,272,000$-20,688,000$-10,376,000$-20,640,000$-22,755,000$-11,505,000$-7,192,000$-34,908,000
    EBITDA$-11,157,000$-7,909,000$11.84M$-18,862,000$-12,482,000$-20,282,000$-10,200,000$-20,514,000$-22,636,000$-11,111,000$-6,847,000$-35,955,000
    EBIT$-12,530,000$-9,333,000$9.62M$-20,241,000$-13,846,000$-21,428,000$-11,312,000$-21,479,000$-23,717,000$-12,404,000$-8,063,000$-35,955,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CDXS

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

    Codexis (CDXS) reported a Q2 loss of $0.13 per share, exceeding the Zacks Consensus Estimate of a $0.17 loss, marking a 23.53% surprise. The company's revenues for the quarter reached $14.92 million, surpassing consensus estimates by 17.20%, although slightly down from $15.33 million year-over-year. Despite beating earnings and revenue estimates, Codexis shares have declined by 8% year-to-date, contrasting with the S&P 500's 13.3% gain.

    Eastern Progress•8/22/26•
    Neutral

    Codexis (NasdaqGS:CDXS) Stock Forecast & Analyst Predictions

    Codexis (CDXS) is forecast to grow earnings and revenue by 55.7% and 20.8% per annum, respectively, though it is expected to remain unprofitable for the next three years. The average analyst price target for CDXS has recently increased to US$7.40, significantly above its current trading price, despite risks such as shareholder dilution, share price volatility, and a limited cash runway. The company is actively developing its ECO Synthesis manufacturing platform for RNA therapeutics, with recent advancements in stereochemistry control and partnerships with CDMOs.

    Simply Wall Street•8/19/26•
    Neutral

    Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen

    Wall Street Zen has downgraded Codexis (NASDAQ:CDXS) from "Hold" to "Sell," causing the stock to fall 2.5% to $1.56, significantly below its 12-month high. Despite beating quarterly earnings expectations with a smaller loss and higher revenue than anticipated, the biotechnology company remains unprofitable, with a negative net margin and projected full-year loss. Institutional investors and hedge funds hold a substantial 78.54% stake in the company.

    MarketBeat•8/15/26•
    Somewhat-Bearish

    Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

    Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movement, making CDXS an attractive investment. The Zacks Rank system, based on earnings estimate revisions, has a strong track record of identifying stocks likely to outperform.

    Yahoo Finance•8/14/26•
    Bullish

    Codexis (CDXS) Stock Rallies On Longer Cash Runway Questions Remain

    Codexis (CDXS) stock rallied 8.1% after its Q2 2026 earnings report, primarily due to management's revised expectation that its cash pile will fund operations through 2028, extending its cash runway. Despite this positive development, the company reported a US$12.0m net loss on US$14.9m in revenue, maintaining questions about its path to profitability and dilution risk. The market appears to be rewarding the extended runway more than near-term revenue softness, while bears point to ongoing losses and past dilution.

    Sahm•8/13/26•
    Neutral

    Frequently Asked Questions About CDXS

    Does CDXS pay dividends?
    Codexis Inc (CDXS) does not currently pay a regular dividend.
    What is CDXS's market cap?
    Codexis Inc (CDXS) has a market capitalization of $174.11M with a current stock price of $1.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In